Regulatory agencies like the FDA and EMA have stringent guidelines for evaluating new cancer drugs. They consider the results from clinical trials, including data on efficacy, safety, and quality of life. Conditional approvals may be granted for drugs that show promise in early trials, but these drugs are often subjected to further post-marketing studies to confirm their benefits and monitor any long-term side effects.
